You are here

IMMUNOGENICS LLC

Company Information
Address
1600 DOVE ST STE 330
NEWPORT BEACH, CA 92660-1418
United States


http://www.immunogenx.com

Information

UEI: DHJSMHJ9BJE5

# of Employees: 7


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes




Success Stories

  1. SBIR-STTR-Tibbetts Award Winner - ImmunogenX, LLC

    2020 Tibbetts Award Winner ImmunogenX, LLC is pioneering eforts in Celiac disease therapy, management, and food safety.                             ...

Award Charts




Award Listing

  1. A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease

    Amount: $1,911,176.00

    The goal of this work is to evaluate the efficacy of a therapeutic agent for protecting individuals with Type 1 diabetes (T1D) and celiac disease (CD) from intestinal and symptomatic distress they suf ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease

    Amount: $2,925,963.00

    The goal of this work is to develop a therapeutic drug that will protect individuals with celiac disease (CD) from intestinal and symptomatic distress they suffer due to minute ingestion of gluten pro ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  3. A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease

    Amount: $299,089.00

    Project Summary AbstractThe goal of this work is to develop a therapeutic drug that will protect individuals with celiac diseaseCDfrom intestinal and symptomatic distress they suffer due to minute ing ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  4. A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease

    Amount: $293,257.00

    Project Summary The goal of this work is to evaluate the efficacy of a therapeutic agent for protecting individuals with TypediabetesT Dand celiac diseaseCDfrom intestinal and symptomatic distress the ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government